Uncategorized
Allergan issues concerns about viability of Valeant’s business model
Allergan filed an investor presentation with the Securities and Exchange Commission outlining its concerns about the fiscal and operational stability of Valeant Pharmaceuticals, the company announced in a press release.According to the release, Allergan retained the financial consultant Alvarez & Marsal and the forensic accounting firm FTI Consulting to analyze issues surrounding the intrinsic value of Valeant’s business model and stock.